SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PSI-697

Cat. No.:	HY-15526		
CAS No.:	851546-61-7		
Molecular Formula:	$C_{21}H_{18}ClNO_3$		
Molecular Weight:	367.83		
Target:	P-selectin		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 45.8 mg/mL (124.51 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Concentration / Solvent / Mass	1 mg	5 mg	10 mg
	1 mM	2.7186 mL	13.5932 mL	27.1865 mL
	5 mM	0.5437 mL	2.7186 mL	5.4373 mL
	10 mM	0.2719 mL	1.3593 mL	2.7186 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PSI-697 is an oral P-selectin inhibitor with an IC_{50} of 125 μM[1].

IC_{50} & Target

IC50: 125 μM (P-selectin)[1]

In Vitro

PSI-697 inhibits the binding of a soluble human P-selectin to PSGL-1, in a reproducible concentration-dependent manner inhibiting 50% of binding at a concentration of 125 μM in vitro[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

PSI-697 (0-50 mg/kg; p.o.) significantly reduces the number of rolling leukocytes by 39% versus vehicle control[1].

PSI-697 (100 mg/kg; p.o.) reduces thrombus weight by 18% relative to vehicle, without prolonging bleeding time in a rat venous thrombosis model[1].

PSI-697 (30 mg/kg; p.o.; daily; 6 days) promotes thrombus resolution and decreases inflammation in a baboon model of venous thrombosis[2].

PSI-697 ((30 mg/kg; i.g.; daily) decreases vein wall injury in a rat stenosis model of venous thrombosis[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 weeks male Sprague-Dawley rat (50-100 g)[1]
Dosage:	0 mg/kg, 30 mg/kg, 50 mg/kg
Administration:	Oral administration
Result:	At an oral dose of 50 mg/kg reduced the number of rolling leukocytes by 39% versus vehicle control.

CUSTOMER VALIDATION

- Chem Eng J. 382 (2020) 122848.
- Cancer Immunol Res. 2022 Apr 12;canimm.0559.2021.
- Int J Nanomedicine. 2021 Aug 24;16:5777-5795.
- Oncogene. 2019 Mar;38(12):2005-2019.
- Thromb Res. 2020 Jan;185:160-166.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Bedard PW et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J Pharmacol Exp Ther.

[2]. Myers DD Jr et al. Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation. Thromb Haemost. 2007 Mar;97(3):400-7.

[3]. Myers DD Jr et al. Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis. J Vasc Surg. 2006 Sep;44(3):625-32.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA